Inhibikase Therapeutics (IKT) Return on Assets (2021 - 2025)
Historic Return on Assets for Inhibikase Therapeutics (IKT) over the last 5 years, with Q3 2025 value amounting to 0.15%.
- Inhibikase Therapeutics' Return on Assets rose 28900.0% to 0.15% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.15%, marking a year-over-year increase of 28900.0%. This contributed to the annual value of 0.51% for FY2024, which is 5100.0% up from last year.
- Inhibikase Therapeutics' Return on Assets amounted to 0.15% in Q3 2025, which was up 28900.0% from 0.2% recorded in Q2 2025.
- In the past 5 years, Inhibikase Therapeutics' Return on Assets ranged from a high of 0.15% in Q3 2025 and a low of 3.04% during Q3 2024
- For the 5-year period, Inhibikase Therapeutics' Return on Assets averaged around 0.78%, with its median value being 0.56% (2024).
- As far as peak fluctuations go, Inhibikase Therapeutics' Return on Assets crashed by -20400bps in 2024, and later surged by 28900bps in 2025.
- Over the past 5 years, Inhibikase Therapeutics' Return on Assets (Quarter) stood at 0.33% in 2021, then tumbled by -102bps to 0.68% in 2022, then crashed by -83bps to 1.24% in 2023, then skyrocketed by 55bps to 0.56% in 2024, then soared by 72bps to 0.15% in 2025.
- Its Return on Assets stands at 0.15% for Q3 2025, versus 0.2% for Q2 2025 and 0.25% for Q1 2025.